BBH

Featured

Investors Clamor for Generic Drug ETF

By Tom LydonMay 6, 2013

Featured

Ups and Downs for ETFs in 2012

By Tom LydonDecember 31, 2012

Featured

Why Biotech ETFs are a Top Sector in 2012

By Tom LydonDecember 19, 2012

Featured

More M&A Deals Could Boost Biotech ETFs

By Tom LydonDecember 11, 2012

Featured

Biotech ETFs Holding Up During Rocky November

By Tom LydonNovember 19, 2012

Featured

Biotech ETFs Cool After Strong Run

By Tom LydonAugust 13, 2012

Featured

Biotech ETFs Weather Market Storm

By John SpenceMay 14, 2012

Featured

Natural Gas ETF Rebound Continues with 9% Weekly Advance

By Tom LydonMay 12, 2012

Featured

Choosing the Right Biotech ETF Exposure

By Tom LydonApril 20, 2012

Featured

Biotech ETFs Break Out

By John SpenceJanuary 19, 2012

Featured

Six HOLDRS Become Van Eck ETFs

By Tom LydonDecember 21, 2011

Featured

HOLDRS Making Transition to Market Vector ETFs

By Tom LydonNovember 23, 2011

New ETFs

Van Eck, Merrill Lynch in Agreement Over HOLDRS

By Tom LydonAugust 15, 2011

Featured

Biotech ETFs Mixed After Gilead Subpoena

By Tom LydonJune 13, 2011

Featured

Biogen Earnings, Drug Data to Lift Biotech ETFs

By John SpenceApril 21, 2011

Featured

5 Biotechnology ETFs to Play Innovation

By Tom LydonFebruary 22, 2011

Featured

Play the Booming Biotech Sector With ETFs

By Tom LydonDecember 21, 2010

Featured

Biotech ETFs: 5 Ways to Play Innovation

By Tom LydonAugust 8, 2010